人表皮生长因子受体2抑制剂靶向治疗胆道恶性肿瘤的研究进展  

Research progress of precise targeted therapy for human epidermal growth factor receptor-2 in biliary tract cancers

作　　者：翁海敏 应杰儿[2] Weng Haimin;Ying Jieer(Second Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou 310053,China;Department of Hepato-Pancreato-Biliary&Gastric Internal Medicine,Zhejiang Cancer Hospital,Hangzhou 310022,China)

机构地区：[1]浙江中医药大学第二临床医学院,杭州310053 [2]浙江省肿瘤医院肝胆胰胃内科,杭州310022

出　　处：《中华肝胆外科杂志》2023年第8期636-640,共5页Chinese Journal of Hepatobiliary Surgery

基　　金：浙江省医药卫生科研项目(2021446186)。

摘　　要：胆道恶性肿瘤(BTC)是一类高度异质性肿瘤。目前全球BTC的治疗需求远未被满足,晚期化疗生存获益有限。随着精准治疗的兴起,晚期BTC可选择的治疗方案越来越多。人表皮生长因子受体2(HER2)抑制剂已在BTC中展开探索,包括单克隆抗体、酪氨酸激酶抑制剂、抗体偶联药物、双特异性抗体等。本文就近年BTC中HER2抑制剂研究进展作一综述,以期为临床提供参考。Biliary tract cancers(BTC)are highly heterogeneous tumours.Currently,the global demand for advanced BTC treatment is far from being met,and the survival benefit from advanced chemotherapy is limited.In recent years,with the rise of precision treatment,there are more and more treatment options available for advanced BTC.Human epidermal growth factor receptor-2(HER2)inhibitors,including monoclonal antibodies,tyrosine kinase inhibitors,antibody drug conjugates,and bispecific antibodies,have been explored in BTC.This article reviews the research progress and prospects of HER2 inhibitors in BTC in recent years,so as to provide a better clinical guidance.

关 键 词：胆道肿瘤 靶向治疗 基因 ERBB-2 

分 类 号：R735.8[医药卫生—肿瘤]